✉news BusinessRetail first seen 11 h ago, last 10 h ago, peak #22
Arrowhead Pharmaceuticals Stock Nears Five-Year High on Phase 3 Win
Original: ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval
Arrowhead Pharmaceuticals shares are on track to reach their highest level in more than five years after positive Phase 3 trial results, with retail investors celebrating the biotech's momentum. The company is reportedly aiming for a broader FDA approval than initially expected, fueling optimism about the commercial potential of its drug pipeline and driving renewed interest in the stock.
Why now: Retail investors are reacting to the Phase 3 breakthrough and prospects of a wider FDA approval pushing the stock to multi-year highs.
Rank over time, top of the chart is #1. 2 snapshots from 11 h ago to 10 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/76521